PRESS RELEASE published on 04/21/2026 at 07:30, 4 months 16 days ago Terms of availability of the preparatory documents for the GM Sensorion provides Preliminary Documents for the Combined Shareholders' General Meeting of May 11, 2026. Shareholders urged to participate in a critical meeting addressing new therapies for hearing loss disorders Biotechnology Shareholders' Meeting Gene Therapy Sensorion Hearing Loss
PRESS RELEASE published on 04/21/2026 at 07:30, 4 months 16 days ago Modalités de mise à disposition des documents préparatoires à l'AG Sensorion annonce la mise à disposition des documents préparatoires à l'Assemblée Générale mixte du 11 mai 2026. Les actionnaires peuvent voter à distance. Contact: contact@sensorion-pharma.com Actionnaires Documents Préparatoires Assemblée Générale Mixte Vote À Distance Sensorion
BRIEF published on 03/23/2026 at 07:35, 5 months 15 days ago Sensorion continues its development in gene therapy for deafness Gene Therapy Congenital Deafness Audiogene Sense-501 Sense-601
BRIEF published on 03/23/2026 at 07:35, 5 months 15 days ago Sensorion Updates on Audiogene Trial and Advances GJB2-GT Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
BRIEF published on 03/23/2026 at 07:35, 5 months 15 days ago Sensorion poursuit son développement en thérapie génique pour la surdité Thérapie Génique SENS-501 Surdité Congénitale Audiogene SENS-601
BRIEF published on 03/23/2026 at 07:35, 5 months 15 days ago Mises à jour de Sensorion sur l'essai Audiogene et les progrès du GJB2-GT Essais Cliniques Thérapie Génique Sensorion Perte Auditive SENS-601
PRESS RELEASE published on 03/23/2026 at 07:30, 5 months 15 days ago Informations privilégiées / Autres communiqués Sensorion publie les données à six mois de l’essai clinique de Phase 1/2 Audiogene pour SENS-501 et poursuit le développement clinique du GJB2-GT (SENS-601) vers une première administration chez l’homme Essai Clinique Thérapie Génique Sensorion Surdité GJB2-GT
BRIEF published on 03/18/2026 at 07:35, 5 months 20 days ago Sensorion Reports 2025 Results and Corporate Updates Financial Results Gene Therapy Sensorion Hearing Loss Sanofi Investment
BRIEF published on 03/18/2026 at 07:35, 5 months 20 days ago Sensorion publie ses résultats 2025 et les dernières nouvelles de l'entreprise Résultats Financiers Thérapie Génique Sensorion Perte Auditive Investissements Sanofi
PRESS RELEASE published on 03/18/2026 at 07:30, 5 months 20 days ago Inside Information / News release on accounts, results Sensorion reports full-year 2025 results, provides corporate update, and announces release of annual report. Key milestones in gene therapies for hearing loss. Financial highlights and future expectations highlighted Financial Highlights Full-year Results Sensorion Gene Therapies Future Milestones
Published on 09/08/2026 at 01:45, 1 hour 15 minutes ago Tunkillia Environmental Scoping Report Approved
Published on 09/05/2026 at 04:05, 2 days 22 hours ago Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 3 days 3 hours ago FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 3 days 4 hours ago Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 3 days 4 hours ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/07/2026 at 19:19, 7 hours 41 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Sales and Adjusted EBIT in Q2 2026/27 above prior-year level – FY outlook maintained
Published on 09/07/2026 at 19:00, 8 hours ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 31 août 2026 au 4 septembre 2026
Published on 09/07/2026 at 18:42, 8 hours 17 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/07/2026 at 18:00, 9 hours ago E-PANGO: e-Pango organise un webinaire avec ses actionnaires
Published on 09/07/2026 at 17:45, 9 hours 15 minutes ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 09/07/2026 at 19:00, 8 hours ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 8 hours ago Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 8 hours 55 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026
Published on 09/07/2026 at 18:05, 8 hours 55 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/08/2026
